title: Enteric-coated mycophenolate sodium experience in liver transplant patients.
abstract: Mycophenolate sodium (EC-MPS) has been shown to be as effective and as safe as mycophenolate mofetil (MMF) in renal transplant patients. Nevertheless, compared to MMF its use in liver transplant patients has been limited. The purpose of this study was to analyze the efficacy of EC-MPS as a primary immunosuppressant or as a replacement for MMF in liver transplant patients. Ninety among 470 liver transplant recipients were receiving or had added an antimetabolite to their immunosuppressant therapy. The most common reason for this change was renal dysfunction (47.8%) or diabetes (32.2%). EC-MPS was started at a median of 30 months after liver transplantation. The mean administered daily dose was 720 mg/d. At least one gastrointestinal symptom was reported by 25 patients. Abdominal pain (16.6%) and diarrhea (14.5%) were the most frequent. EC-MPS had to be discontinued in two patients, while six others required dose reduction to resolve the symptoms. Hematological adverse events were infrequent: three patients had leukopenia and one, anemia, all of which responded to dosage reduction. There was a creatinine reduction within 6 months of drug commencement and maintenance of the lower creatinine levels at 1 year among patients who began EC-MPS for renal dysfunction. Serum low-density lipoprotein cholesterol and triglyceride levels were significantly lower among patients on EC-MPS than on MMF. In conclusion, EC-MPS appears to have a similar efficacy and safety profile as MMF in liver transplant patients. Hematological and gastrointestinal adverse events were infrequent; seldom had the drug to be discontinued.
authors.affiliation: Grupo de Transplante Hepático, Santa Casa de Porto Alegre, Porto Alegre, Brazil. txhepatico@santacasa.tche.br
authors.forename: G P C
authors.initials: GP
authors.lastname: Cantisani
authors.forename: M L
authors.initials: ML
authors.lastname: Zanotelli
authors.forename: A L M
authors.initials: AL
authors.lastname: Gleisner
authors.forename: A
authors.initials: A
authors.lastname: de Mello Brandão
authors.forename: C A
authors.initials: CA
authors.lastname: Marroni
mesh_terms: D001424:Bacterial Infections / Q000188:drug therapy / Q000453:epidemiology; D005260:Female; D005767:Gastrointestinal Diseases / Q000453:epidemiology; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology; D016031:Liver Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*; D013608:Tablets, Enteric-Coated
chemical_list: D013608:Tablets, Enteric-Coated; D009173:Mycophenolic Acid